1. China Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Jinxin Fertility Group Ltd.

Jinxin Fertility Group Ltd.

0.25
EUR
0.00
(0.00%)
660.62MMarket Cap
Mar 31Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.15
0.28
0.39
0.75
0.59
0.74
0.95
1.04
1.05
0.97
- -
Basic EPS, GAAP
0.04
0.04
0.07
0.19
0.1
0.14
0.05
0.13
0.11
-0.36
- -
Free Cash Flow per Basic Share
0.04
0.01
0.14
0.08
-0.01
0.11
-0.17
0.19
0.14
0.12
- -
Dividend per Share
- -
0.03
0.05
0.15
0.06
- -
0.06
- -
0.06
- -
- -
Book Value per Share
0.03
0.39
1.83
3.09
3
3.41
3.43
3.71
3.84
3.46
3.46
Tangible Book Value per Share
0.03
0.03
-0.03
1.26
1.03
0.25
-0.42
0.14
0.21
0.2
0.2
Basic Weighted Avg Shares
2,381
2,381
2,381
2,199
2,400
2,478
2,496
2,676
2,681
2,742
2,694
Sales/Revenue/Turnover
346
663
922
1,648
1,426
1,839
2,364
2,789
2,812
2,649
- -
Operating Margin (%)
30.61
35.7
28.71
28.56
17.21
20.57
10.72
18.4
16.14
4.12
- -
Depreciation Expense
14
35
42
113
130
169
260
285
276
345
- -
Net Income, GAAP
88
99
167
410
252
340
121
345
283
-976
- -
Effective Tax Rate (%)
5.21
17.81
23.31
23.22
25.39
22.76
23.57
25.26
30.22
- -
- -
Profit Margin (%)
25.28
14.9
18.07
24.85
17.64
18.48
5.12
12.36
10.07
-36.85
- -
Working Capital
-448
331
59
2,990
2,097
1,472
-860
-347
-1,030
-192
-192
LT Debt
- -
- -
- -
153
354
1,990
2,447
1,729
1,274
2,173
2,173
Total Equity
101
1,362
4,500
7,642
7,462
8,753
8,735
10,187
10,354
9,199
9,199
Return on Invested Capital (%)
- -
25.53
6.66
5.73
2.37
3.09
1.4
2.79
2.46
- -
- -
Return on Capital (%)
- -
-0.13
4.13
6.58
3.22
3.66
1.51
3.14
2.59
- -
- -
Return on Common Equity (%)
- -
19.62
6.3
6.89
3.4
4.29
1.41
3.68
2.78
-10.05
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1,331
542
675
LT Borrowings
993
1,904
1,840
LT Finance Leases
281
363
333
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,676
2,681
2,641
Market Capitalization
6,710
7,288
5,428

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,090
1,190
1,249
Cash, Cash Equivalents & STI
571
720
906
Accounts Receivable, Net
234
199
138
Inventories
51
46
56
Total Current Liabilities
2,119
1,338
1,441
Payables & Accruals
- -
- -
- -
ST Debt
1,331
542
675
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.84%
-11.16%
Free Cash Flow
- -
-477.67%
-11.56%
Net Income, GAAP
- -
-61.47%
-444.81%
Sales/Revenue/Turnover
- -
14.1%
-5.78%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2,789
2024
- -
- -
2,812
2025
- -
- -
2,649

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.13
2024
- -
- -
0.11
2025
- -
- -
-0.36

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
0.06
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yang Dong
Full Time Employees
3,494
Sector
Health services
Industry
Medical/Nursing services
Address
No. 301, North Jingsha Road Chengdu SI China 610000
IPO Date
Jun 25, 2019
Website
jxr-fertility.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Jinxin Fertility Group Limited operates as an investment holding company specializing in assisted reproductive services (ARS) in China and the United States. The company offers a comprehensive range of fertility treatment solutions including artificial insemination using either husband’s or donor sperm, conventional in vitro fertilization (IVF), embryo transfer, and IVF with intracytoplasmic sperm injection. It also provides related services such as pre-implantation genetic screening, nutrition guidance, Chinese medicine treatments, psychological counseling, obstetrics, gynecology, pediatrics, postpartum and rehabilitation care, as well as sales of medical consumables and equipment. Additionally, Jinxin engages in investment management, management consultancy, and real estate development and operation activities. Founded in 1951 and headquartered in Chengdu, China, the company operates a network of fertility clinics serving primarily Mainland China with expanding operations including the United States and Southeast Asia. In recent major developments, Jinxin Fertility completed the acquisition of a 5% stake in PT Morula Indonesia as part of a strategic cooperation to expand its presence in the Southeast Asian IVF market, alongside ongoing investments in property, plant, and equipment to expand clinic capacity and service offerings. The group also completed an internal restructuring in late 2022 to diversify and integrate its full lifecycle fertility services, covering preparation, IVF, prenatal, childbirth, and postpartum care, reinforcing its position as a leading ARS provider in the region. Its business segments encompass fertility treatment, medical services, scientific research, commercialization of IVF projects, and ancillary healthcare services.